Trial Profile

A phase 2b/3 study of Oral PTH (1-34) in Patients With Hypoparathyroidism

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 20 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teriparatide (Primary)
Indications Hypoparathyroidism
Focus Therapeutic Use
Acronyms HypoPT

Most Recent Events

10 Nov 2022 According to an Entera bio media release, the company expects new formulation of EB612 PTH tablets for hypoparathyroidism to re-enter the clinic in 2023
20 May 2021 According to an Entera bio media release, the company expects to initiate this study in 2022.
19 Nov 2020 According to an Entera bio media release, the company expects to initiate this study in 2021 or 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com